Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue. In the paper "Bimagrumab and semaglutide alone or in combination for the treatment of obesity: a phase 2 randomized clinical trial," published Monday in the journal Nature Medicine, Dr. Steven Heymsfield of Pennington Biomedical Research Center describes the results of the BELIEVE study, which showed that the therapy combination addressed lean mass loss associated with GLP-1-based therapies.